Omniscient secured $27.2 million [1] in a Series D funding round on May 29, 2026, to expand its AI-driven brain analysis technology.
This investment allows the company to scale its FDA-cleared Quicktome platform globally. By accelerating the commercialization of personalized brain care, Omniscient aims to improve how medical professionals analyze brain health through artificial intelligence.
The funding round was oversubscribed and totaled $27.2 million [1], which is approximately AU$41.1 million [1]. The company issued the announcement from San Francisco, California.
Omniscient specializes in AI-enabled brain analysis. The company intends to use the new capital to drive the adoption of the Quicktome platform, a tool designed to provide more precise, personalized care for patients with brain-related conditions.
The company said the funds will be used to accelerate the commercialization of its technology and expand its services worldwide. This expansion follows the platform's clearance by the U.S. Food and Drug Administration, which allows the technology to be marketed for clinical use.
By integrating AI into brain analysis, the platform seeks to reduce the time and complexity involved in diagnosing and treating neurological issues. The Series D round represents a significant step in the company's transition from a development-stage entity to a commercial provider of medical technology.
“Omniscient secured $27.2 million in a Series D funding round”
The successful oversubscription of this funding round indicates strong investor confidence in AI-driven diagnostics. As the Quicktome platform moves from FDA clearance to global commercialization, the focus shifts to whether the technology can be integrated into standard clinical workflows at scale to improve patient outcomes.
